Clinical trials: Coagulation
Lactic Acidosis, Blood Glucose, High
Nitroglycerin Infusion During Cardiac Surgery
Hypothermic cardiopulmonary bypass results in peripheral vasoconstriction and heparin trapping. Hypoperfusion and ischemic-reperfusion injury are associated with systemic inflammatory response, while insufficient and delayed…
- Trial name
- NCT01901419
- Testing
- Nitroglycerin infusion
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Tri-Service General Hospital (TSGH)
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders. II. Explore the mutations within each syndrome to better understand the genetics of these disorders. III.
- Conditions
- X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
- Trial name
- NCT00004341
- Where
- United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hemophilia B
Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea
Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea. Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.
- Trial name
- NCT02922231
- Testing
- RIXUBIS
- Where
- 5 sites in South Korea
- Volunteers
- 57 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII
The ability of a new recombinant porcine coagulation factor VIII, B-domain deleted (called "OBI-1"), to control the non-life- or limb-threatening bleeding episodes patients with hemophilia A commonly develop is being evaluated.
- Trial name
- NCT00245245
- Testing
- recombinant porcine coagulation factor VIII (OBI-1)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Octagen Corporation
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Severe Hemophilia A
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with…
- Trial name
- NCT02954575
- Testing
- Wilate
- Where
- 7 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 57 people
- Sponsor
- Octapharma
Pneumonia, Sepsis
Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis
Pneumonia is a lung infection that can cause serious complications, especially when accompanied by sepsis. Sepsis can trigger excessive inflammation and abnormal blood clotting, potentially leading to organ damage and delayed…
- Conditions
- Pneumonia, Sepsis, Blood Coagulation Disorders
- Trial name
- NCT07892794
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Sebelas Maret
Wiskott-Aldrich Syndrome
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome…
- Trial name
- NCT03837483
- Testing
- OTL-103
- Where
- 2 sites in United States, Italy
- Volunteers
- 10 people
- Sponsor
- Fondazione Telethon
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
For patients with leukemia who have not responded to or have progressed after an initial response to standard therapy, therapeutic options are limited.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease, Chronic Myeloid Leukemia
- Trial name
- NCT01167166
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Traws Pharma, Inc.
Hemophilia A and B, Liver Transplantation
ATHN 11: Liver Transplantation Outcomes Study
This study is designed as a multi-center, observational cohort study of participants with hemophilia A and B who have and have not undergone liver transplantation.
- Trial name
- HOT (NCT04055051)
- Where
- 15 sites in United States
- Volunteers
- 86 people
- Sponsor
- American Thrombosis and Hemostasis Network
Congenital Bleeding Disorder, Glanzmann's Disease
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
This study is conducted in Asia. The aim of the study is to evaluate the safety and efficacy of NovoSeven® (activated recombinant factor VII, eptacog alfa (activated)) during bleeding episodes and for the prevention of bleeding…
- Trial name
- NCT01876745
- Testing
- eptacog alfa (activated)
- Where
- Japan
- Volunteers
- 4 people
- Sponsor
- Novo Nordisk A/S
Hemophilia B
RIXUBIS PMS India (RIXUBIS PMS)
The purpose of this study is to characterize the safety and describe the effectiveness of RIXUBIS in routine clinical practice.
- Trial name
- NCT03565237
- Testing
- RIXUBIS: On-Demand, RIXUBIS: Prophylaxis
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Baxalta now part of Shire
Accident, Traffic
Correlation Between Coagulation Profiles And Injury Severity In Road Traffic Accidents Patients at Dera Ismail Khan
Trauma-induced coagulopathy (TIC), also known as acute traumatic coagulopathy (ATC), is a common condition in patients with severe trauma, particularly in road traffic accident (RTA) victims.
- Trial name
- NCT07051395
- Testing
- Road Traffic Accidents Patient
- Where
- Pakistan
- Volunteers
- 230 people
- Sponsor
- Superior University
Immune Thrombocytopenia
ATRA for Management of Primary ITP
A multicenter, randomized, double-blind placebo-controlled study to report the efficacy and safety of all-trans etinoic acid compared to placebo for the treatment of adults with corticosteriod-resistant/relapsed primary immune…
- Trial name
- NCT07597395
- Testing
- all-trans retinoic acid (ATRA)
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Peking University People's Hospital
Cervical Precancer
Development, Field Testing and Evaluation of the Efficacy of a Hand-held, Portable and Affordable Thermo-coagulator to Prevent Cervical Cancer in Low- and Middle-income Countries
This project develops, tests and produces a lightweight, cordless, battery driven and rechargeable hand-held device for treating cervical precancer (Liger Thermal Coagulator).
- Trial name
- DELTA (NCT02956239)
- Testing
- Thermocoagulation (device), Cryotherapy (device), LEEP (device)
- Where
- Zambia
- Volunteers
- 3,124 people
- Sponsor
- International Agency for Research on Cancer
Hemophilia A
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Primary Objective: To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: To evaluate the efficacy of BIVV001 as a prophylaxis treatment.
- Trial name
- XTEND-ed (NCT04644575)
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 85 sites in United States, Argentina and 21 more
- Volunteers
- 261 people
- Sponsor
- Bioverativ, a Sanofi company
Hemophilia A With Inhibitor
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII replacement therapy for patients with inhibitors to…
- Trial name
- NCT04592692
- Testing
- PEGylated Liposome (PEGLip)
- Where
- 5 sites in Russia
- Volunteers
- 20 people
- Sponsor
- Ascension Healthcare Development Limited
Blood Coagulation Tests ( INR, APTT)
Sugammadex Reversal of Neuromuscular Blockade and Postoperative Bleeding
Sugammadex is new drug that is used for reversal of rocuronium induced muscle relaxation. benefits of reversal of neuromuscular blockade appears to be of great value in living donor liver transplant recipients.
- Trial name
- Suga_bleeding (NCT02939430)
- Testing
- Sugammadex intravenous, Intravenous neostigmine and atropine
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Mansoura University
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who…
- Trial name
- VAY2EXPLORE (NCT07421167)
- Testing
- ianalumab, thrombopoietin receptor agonist (TPO-RA)
- Where
- 19 sites in United States
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP).
- Trial name
- advance NEXT (NCT06544499)
- Testing
- Efgartigimod IV
- Where
- 94 sites in United States, Austria and 15 more
- Volunteers
- 69 people
- Sponsor
- argenx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.